Literature DB >> 2897213

Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease.

O Eradiri1, F Jamali, A B Thomson.   

Abstract

The influence of prednisone(PR), sulfasalazine(SZ), cimetidine(CM), and phenobarbital(PB) on the pharmacokinetics of metronidazole was investigated in six Crohn's patients. Metronidazole was first administered alone (250 mg bid, po) and then with prednisone (10 mg bid, po), sulfasalazine (1 g bid, po), cimetidine (600 mg bid) or phenobarbital (60 mg bid, po). Each regimen was followed for 6 days and sampling of blood and urine was carried out on the 7th day after the first dose of each regimen. Plasma and urine samples were analysed for the drug and its two principal metabolites, hydroxymetronidazole and metronidazole-1-acetic acid, by HPLC. When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1. The disposition kinetics of metronidazole and its metabolites was not altered by CM and SZ. Induction of metabolism of metronidazole by PR was made manifest in significant increases in oral clearance of the former and urinary excretion of the hydroxy metabolite, and significant decrease in AUC of the parent compound. PB also induced the metabolism of metronidazole. This induction was reflected in significant increases in the oral clearance of metronidazole and AUC of the hydroxy metabolite as well as significant decreases in AUC, half-life, and urinary excretion of the parent drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897213     DOI: 10.1002/bod.2510090210

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  5 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 2.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

4.  Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.

Authors:  Ivy H Song; Julie Borland; Shuguang Chen; Paul Savina; Amanda F Peppercorn; Stephen Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.